

**2018 Mo-99 TOPICAL MEETING ON
MOLYBDENUM-99 PRODUCTION TECHNOLOGY DEVELOPMENT**

**SEPTEMBER 23-26, 2018
HILTON KNOXVILLE HOTEL
KNOXVILLE, TN**

The Downstream Effect of Mo99 Supply Chain Issues

John Witkowski
President

UPPI, LLC. 5400 Laurel Springs Parkway Suite 405 Suwanee, Georgia 30024, USA.

ABSTRACT

Mo99 supply chain issues plagued the U.S. nuclear pharmacy industry late in 2017, and in 2018, with situations resulting in a lack of the Mo99 generator product, and occasions of undersized radioactivity in the Mo99 generators. Abrupt or prolonged supply disruption produces a downstream effect to the nuclear pharmacy, the hospital and free-standing imaging centers. In a time when radiology and nuclear imaging departments are actively trying to manage the costs associated with a no-show patient, what happens when the radiopharmaceutical unit dose is a no-show? This presentation provides the factors encountered by UPPI members dealing with the delivery of time critical Tc99m labeled patient doses during supply chain disruptions. Requisite with delivering patient dose demands, UPPI continues strategic initiatives to increase the Q9969 added-on reimbursements and to advocate a change into a permanent reimbursement code for the molecular imaging community. An update of UPPI activities is also provided.